Artículo original
Evaluación de los motivos del cambio de tratamiento para la vejiga hiperactiva
Assessment of reasons for overactive bladder treatment change
D. Castroa,
, P. Mirandab, F. Sánchez-Ballesterc, D. Arumid, I. Lizarragad, C. Ebele, en representación del grupo de estudio Impacta
Autor para correspondencia
a Servicio de Urología, Hospital Universitario de Canarias, Santa Cruz de Tenerife, España
b Servicio de Ginecología, Hospital Universitario de Fuenlabrada, Madrid, España
c Servicio de Urología, Consorcio Hospital General Universitario, Valencia, España
d Pfizer, Madrid, España
e Pfizer, Paris, Francia
Leído
3189
Vecesse ha leído el artículo
776
Total PDF
2413
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 3 | 3 |
| 2025 11 | 0 | 19 | 19 |
| 2025 10 | 0 | 10 | 10 |
| 2025 9 | 0 | 7 | 7 |
| 2025 8 | 0 | 5 | 5 |
| 2025 7 | 0 | 6 | 6 |
| 2025 6 | 0 | 4 | 4 |
| 2025 5 | 0 | 5 | 5 |
| 2025 4 | 0 | 2 | 2 |
| 2025 3 | 0 | 1 | 1 |
| 2025 1 | 0 | 1 | 1 |
| 2024 12 | 0 | 1 | 1 |
| 2024 11 | 0 | 1 | 1 |
| 2024 10 | 0 | 1 | 1 |
| 2024 7 | 0 | 2 | 2 |
| 2024 3 | 0 | 4 | 4 |
| 2024 1 | 0 | 3 | 3 |
| 2023 12 | 0 | 4 | 4 |
| 2023 11 | 0 | 1 | 1 |
| 2023 10 | 0 | 8 | 8 |
| 2023 9 | 0 | 12 | 12 |
| 2023 7 | 0 | 4 | 4 |
| 2023 6 | 0 | 5 | 5 |
| 2023 5 | 0 | 2 | 2 |
| 2023 3 | 1 | 6 | 7 |
| 2023 2 | 0 | 1 | 1 |
| 2022 1 | 0 | 2 | 2 |
| 2022 11 | 0 | 2 | 2 |
| 2022 10 | 0 | 2 | 2 |
| 2022 8 | 0 | 3 | 3 |
| 2022 6 | 0 | 1 | 1 |
| 2022 5 | 0 | 1 | 1 |
| 2022 2 | 0 | 1 | 1 |
| 2021 1 | 0 | 1 | 1 |
| 2021 10 | 0 | 1 | 1 |
| 2021 8 | 0 | 2 | 2 |
| 2021 7 | 0 | 2 | 2 |
| 2021 5 | 0 | 2 | 2 |
| 2021 4 | 0 | 2 | 2 |
| 2021 3 | 0 | 14 | 14 |
| 2021 2 | 0 | 1 | 1 |
| 2020 1 | 0 | 2 | 2 |
| 2020 11 | 0 | 1 | 1 |
| 2020 10 | 0 | 1 | 1 |
| 2020 6 | 0 | 1 | 1 |
| 2020 5 | 0 | 4 | 4 |
| 2020 4 | 0 | 2 | 2 |
| 2020 3 | 0 | 3 | 3 |
| 2020 2 | 0 | 6 | 6 |
| 2019 12 | 0 | 1 | 1 |
| 2019 8 | 0 | 2 | 2 |
| 2019 7 | 0 | 3 | 3 |
| 2019 6 | 0 | 13 | 13 |
| 2019 5 | 0 | 24 | 24 |
| 2019 4 | 1 | 16 | 17 |
| 2019 3 | 0 | 1 | 1 |
| 2019 2 | 0 | 1 | 1 |
| 2018 12 | 0 | 3 | 3 |
| 2018 8 | 1 | 0 | 1 |
| 2018 7 | 1 | 0 | 1 |
| 2018 2 | 3 | 4 | 7 |
| 2018 1 | 6 | 0 | 6 |
| 2017 12 | 12 | 0 | 12 |
| 2017 11 | 6 | 1 | 7 |
| 2017 10 | 8 | 6 | 14 |
| 2017 9 | 14 | 4 | 18 |
| 2017 8 | 11 | 3 | 14 |
| 2017 7 | 10 | 1 | 11 |
| 2017 6 | 13 | 10 | 23 |
| 2017 5 | 8 | 5 | 13 |
| 2017 4 | 7 | 51 | 58 |
| 2017 3 | 11 | 47 | 58 |
| 2017 2 | 13 | 16 | 29 |
| 2016 1 | 10 | 4 | 14 |
| 2016 12 | 22 | 7 | 29 |
| 2016 11 | 27 | 8 | 35 |
| 2016 10 | 45 | 7 | 52 |
| 2016 9 | 23 | 6 | 29 |
| 2016 8 | 32 | 6 | 38 |
| 2016 7 | 14 | 2 | 16 |
| 2016 6 | 27 | 24 | 51 |
| 2016 5 | 24 | 14 | 38 |
| 2016 4 | 23 | 20 | 43 |
| 2016 3 | 25 | 17 | 42 |
| 2016 2 | 17 | 16 | 33 |
| 2015 1 | 24 | 16 | 40 |
| 2015 12 | 25 | 19 | 44 |
| 2015 11 | 23 | 14 | 37 |
| 2015 10 | 31 | 16 | 47 |
| 2015 9 | 19 | 8 | 27 |
| 2015 8 | 24 | 11 | 35 |
| 2015 7 | 11 | 7 | 18 |
| 2015 6 | 9 | 2 | 11 |
| 2015 5 | 11 | 8 | 19 |
| 2015 4 | 30 | 19 | 49 |
| 2015 3 | 21 | 10 | 31 |
| 2015 2 | 37 | 4 | 41 |
| 2015 1 | 36 | 8 | 44 |
| 2014 12 | 36 | 11 | 47 |
| 2014 11 | 31 | 9 | 40 |
| 2014 10 | 62 | 15 | 77 |
| 2014 9 | 35 | 3 | 38 |
| 2014 8 | 38 | 5 | 43 |
| 2014 7 | 23 | 6 | 29 |
| 2014 6 | 34 | 9 | 43 |
| 2014 5 | 24 | 10 | 34 |
| 2014 4 | 16 | 8 | 24 |
| 2014 3 | 25 | 7 | 32 |
| 2014 2 | 22 | 7 | 29 |
| 2014 1 | 30 | 3 | 33 |
| 2013 12 | 31 | 6 | 37 |
| 2013 11 | 22 | 8 | 30 |
| 2013 10 | 12 | 3 | 15 |
| 2013 9 | 15 | 4 | 19 |
| 2013 8 | 17 | 2 | 19 |
| 2013 7 | 7 | 0 | 7 |
| 2011 2 | 1217 | 0 | 1217 |
Mostrar todo
